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Abstract
Studies have indicated that measuring biochemical measures of
epithelial injury in plasma and alveolar fluid may be useful in
predicting outcome in acute lung injury. The present commentary
briefly reviews the evidence supporting the use of these
biochemical biomarkers of epithelial injury in acute lung injury, and
in particular KL-6, as well as their limitations. The article additionally
proposes the need for physiological markers of epithelial function
to complement current biochemical biomarkers.
In the previous issue of Critical Care Nathani and colleagues
have assessed KL-6, a specific marker of type 2 alveolar
epithelial cell injury, as a biomarker in acute lung injury (ALI)
[1]. Biomarkers allow identification of patients at risk of
developing disease or can be used as surrogate measures for
clinical outcomes. Additionally, measuring biological markers
may be a valuable tool in understanding disease patho-
genesis. In ALI, the alveolar capillary barrier is disrupted and
the alveolar epithelial cell function is critical to the recovery
from ALI/acute respiratory distress syndrome (ARDS) [2].
This knowledge provides a rationale for measurement of
alveolar epithelial cell injury using surrogate biochemical
measures such as KL-6, as a biomarker of ALI.
In the study of Nathani and colleagues, plasma and broncho-
alveolar lavage samples were collected following inclusion
and on day 4 from 30 ventilated ALI patients, from 12
patients at risk of developing ALI and from 10 nonsmoking
volunteers free of respiratory disease The study therefore had
the benefit of allowing the investigators to look at KL-6 both
in physiological and pathological states. The important
findings from the study are that plasma KL-6 levels are
increased in patients with ALI, plasma KL-6 correlates with
the severity of lung injury and plasma KL-6 is significantly
elevated in nonsurvivors compared with survivors. Further-
more bronchoalveolar lavage KL-6 is elevated in patients with
ALI and is higher in nonsurvivors. KL-6 did not identify
patients at risk of developing ALI. These findings extend the
previous data showing KL-6 is elevated in plasma and
epithelial lining fluid in ALI [3,4].
In relation to KL-6 in ALI, questions that still remain to be
answered include the specificity of the type 2 epithelial cell
as the source of KL-6 [5] as well as a need to confirm
whether KL-6 elevation reflects epithelial cell injury,
regeneration or secretion in response to inflammatory
mediators. In addition, mechanical ventilation is known to
cause epithelial injury [6], and an important area in which
biomarkers may be valuable is in the assessment of ventilator-
associated lung injury. Increased surfactant protein D is
associated with injurious ventilation strategies [7], and it
would be interesting to know the effects of mechanical
ventilation on KL-6.
Regardless of these outstanding questions, Nathani and
colleagues’ work – together with other data showing that
elevated surfactant protein D, a type 2 epithelial cell product,
is associated with a worse clinical outcome in ALI/ARDS [7]
and that the Receptor for Advanced Glycation End-products,
an alveolar type 1 epithelial cell-associated protein, is
increased in patients with ALI [8] – implicates epithelial cell
damage as an important determinant of outcome and implies
the potential for alveolar epithelial cell biomarkers to predict
outcome in ALI. Further, these data support the central role of
epithelial injury in the pathogenesis of ALI.
Notable limitations of all these surrogate biomarkers exist;
they do not directly measure epithelial function, and they
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require laboratory analysis and therefore cannot be
performed by a clinician at the bedside. Additionally, there is
no biomarker of epithelial function that reliably identifies
patients at risk of ALI who will develop ALI. There is therefore
a need to develop additional functional measures of epithelial
activity.
One such functional measure that merits further research is
nasal potential difference. The resolution of pulmonary
oedema from the alveolar space, which is dependent on
alveolar fluid clearance, is critical to the recovery from
ALI/ARDS. Alveolar fluid clearance depends on active
transport of sodium across a functioning alveolar epithelium.
Ion transport across the epithelium generates a transepithelial
potential difference [9]. Although this cannot be measured at
the alveolus, the potential difference can be measured readily
across the nasal epithelium. Measuring nasal potential
difference is a simple noninvasive measurement easily
undertaken repeatedly at the bedside. In an animal model,
measurement of nasal potential difference correlated with
alveolar fluid clearance [10]. This observation supports the
hypothesis that nasal potential difference measurement may be
a surrogate marker for alveolar epithelial function.
Furthermore, premature infants with pulmonary oedema [11]
and patients susceptible to high-altitude pulmonary oedema
[12] have reduced nasal transepithelial sodium resorption, as
measured by the baseline nasal potential difference,
indicating that nasal potential difference measurement may
be able to identify patients at risk of developing ALI.
Although further work validating such functional measures of
epithelial activity is required, it is probable that as well as
biochemical measures such as KL-6, as demonstrated by
Nathani and colleagues, future biomarkers in ALI will combine
both biochemical and functional measures.
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